TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03001245

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Counseling
Description: Interpersonal Counseling 1+6 sessions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Psychosocial treatment 1+6 sessions guided by the professional's standard professional principles and routinely available methods
Study: NCT00459914

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cpap treatment during sleep
Description: CPAP
Study: NCT04019886

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurophysiological Facilitation of Respiration
Description: Six neuro-facilitation techniques will be given to experimental group. Each technique will be given for 5 seconds hold with 5 repetitions and two sets.
Study: NCT01741155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPI-1620
Description: SPI-1620 11 μg/m2 administered intravenously over one minute.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPI-1620
Description: SPI-1620 11 μg/m2 administered intravenously over one minute.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel: 75 mg/m2 administered as IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel: 75 mg/m2 administered as IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel: 75 mg/m2 administered as IV infusion.
Study: NCT03534999

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental. This was the group that received TENS
Description: Patients that were on TENS . They were treated twice daily for 5 days. VAS and Hip Score scale were used to assess the pain intensity and disability level

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No intervention
Description: Patients in this group were on their drugs only. There was no physiotherapy intervention for the patient. VAS and Hip Score scale were used to ascertain the pain intensity and hip disability at the before the treatment and after the treatment
Study: NCT01048099

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRO Onc Assay and Treatment
Description: Patients with HER2-negative metastatic breast cancer will be identified, and blood specimens will be obtained from each participant. The PRO Onc Assay will be performed on CTCs isolated from these specimens. When clinically indicated, fine needle aspiration biopsy will also be obtained and submitted for the PRO Onc Assay.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 8 mg/kg IV loading dose, followed by 6 mg /kg IV every 3 weeks until progressive disease or unacceptable toxicity with evaluations performed every 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: 840 mg IV loading dose, followed by 420 IV every 3 weeks until progressive disease or unacceptable toxicity with evaluations performed every 8 weeks
Study: NCT01056913

Intervention type: DEVICE
Group type: OTHER
Intervention: Compression Anastomosis Device
Description: Restoring intestinal continuity using the NITI CAR27 device

Intervention type: OTHER
Group type: OTHER
Intervention: follow-up colonoscopy
Description: endoscopic exploration of anastomosis after complete healing
Study: NCT02146820

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GentleMax system
Description: Picosecond Laser System for the Treatment of Pigmented Lesions
Study: NCT02374437

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aramchol
Description: PART A: Subjects will receive single dose of 200 or 400 mg Aramchol PART B: Subjects will receive single dose of 600 mg Aramchol under fasting or fed conditions ( following a crossover between the groups) PART C: subjects will be equally randomized to receive either 200 mg, 400 mg, 600 mg or placebo tablets for ten consecutive days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aramchol
Description: PART A: Subjects will receive single dose of 200 or 400 mg Aramchol PART B: Subjects will receive single dose of 600 mg Aramchol under fasting or fed conditions ( following a crossover between the groups) PART C: subjects will be equally randomized to receive either 200 mg, 400 mg, 600 mg or placebo tablets for ten consecutive days.
Study: NCT01449786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rMal d 1
Description: 25 µg daily as sublingually administered drops, 16 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rBet v 1
Description: 25 µg daily administered sublingually as drops over 16 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo drops
Description: 25 µg of placebo Drops daily administered sublingually over 16 weeks
Study: NCT02922205

Intervention type: DEVICE
Intervention: Endoscopic Linear Cutter Stapler and reloads
Description: Endoscopic Linear Cutter Stapler and reloads
Study: NCT02967276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin XR
Description: 500 mg tablet: They take 1-5 tablets of 500 mg after dinner. Starting dose of Metformin XR 500 mg. It will have an increase of 500 mg/day each week up to the maximum tolerance from the 2500 mg / day, during the 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 4 mg tablet: Patients will use 40 mg per day. They take 5-10 tablets 4mg after breakfast and lunch. Patients over age 75 will use 20 mg / day.
Study: NCT01296763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 70 mg/m2 IV, Days 1 and 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 25 mg/m2 IV, Days 1 and 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib (for levels 1 and 5)
Description: Olaparib 100 mg bid oral, Days 1 and 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib (for dose level 2)
Description: Olaparib 100mg bid oral, Day 1-3, Day 8-10

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin-C
Description: Mitomycin 5 mg/m2 IV, Day 1
Study: NCT03964051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab Injection
Description: Omalizumab 300 mg for subcutaneous injection
Study: NCT02036437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misotac® Sigma Pharmaceutical Industries
Description: The solution will be orally administrated every two hours (maximum 12 hours) until adequate uterine contractions obtained (3 per 10 minutes each lasting 40-60 seconds) and then stopped. The initial dose of 20 ml (20 ug) will be increased to 40 ml (40ug) after two doses if there are no contractions. The timing and strength of contractions will be assessed by abdominal palpation. If the contractions are inadequate, augmentation of the active phase of labor will be attempted by hourly-titrated oral misoprostol (20 ml) +/- amniotomy. If the uterine contractions are judged to be adequate, the next dose of misoprostol will be omitted.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dinoprostone 3 mg
Description: Dinoprostone 3 mg (Dinoglandin® Alexandria Co. for Pharmaceuticals) will be inserted in the posterior vaginal fornix and repeated after six hours if contractions are inadequate (i.e. two doses maximum). If the contractions become inadequate, augmentation of the active phase of labor will be attempted by Syntocinon (oxytocin) infusion +/- amniotomy.
Study: NCT04461769

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Electrical Stimulation
Description: Oscillating electrical current

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Electrical Stimulation
Description: Oscillating electrical current
Study: NCT02374437

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aramchol
Description: PART A: Subjects will receive single dose of 200 or 400 mg Aramchol PART B: Subjects will receive single dose of 600 mg Aramchol under fasting or fed conditions ( following a crossover between the groups) PART C: subjects will be equally randomized to receive either 200 mg, 400 mg, 600 mg or placebo tablets for ten consecutive days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aramchol
Description: PART A: Subjects will receive single dose of 200 or 400 mg Aramchol PART B: Subjects will receive single dose of 600 mg Aramchol under fasting or fed conditions ( following a crossover between the groups) PART C: subjects will be equally randomized to receive either 200 mg, 400 mg, 600 mg or placebo tablets for ten consecutive days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aramchol
Description: PART A: Subjects will receive single dose of 200 or 400 mg Aramchol PART B: Subjects will receive single dose of 600 mg Aramchol under fasting or fed conditions ( following a crossover between the groups) PART C: subjects will be equally randomized to receive either 200 mg, 400 mg, 600 mg or placebo tablets for ten consecutive days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aramchol
Description: PART A: Subjects will receive single dose of 200 or 400 mg Aramchol PART B: Subjects will receive single dose of 600 mg Aramchol under fasting or fed conditions ( following a crossover between the groups) PART C: subjects will be equally randomized to receive either 200 mg, 400 mg, 600 mg or placebo tablets for ten consecutive days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aramchol
Description: PART A: Subjects will receive single dose of 200 or 400 mg Aramchol PART B: Subjects will receive single dose of 600 mg Aramchol under fasting or fed conditions ( following a crossover between the groups) PART C: subjects will be equally randomized to receive either 200 mg, 400 mg, 600 mg or placebo tablets for ten consecutive days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PART C: subjects will be equally randomized to receive either 200 mg, 400 mg, 600 mg or placebo tablets for ten consecutive days.
Study: NCT04505995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine and homoharringtonine
Description: Concommitant use of azacitidine and homoharringtonine
Study: NCT03318211

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: Intravenous ampules of MgSo4 was given to only to control group after delivery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: Intravenous ampules of MgSo4 was given to only to control group after delivery
Study: NCT03227484

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 25mg
Description: Once daily over 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Once daily over 8 weeks
Study: NCT03171168

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AposTherapy
Description: AposTherapy is a home-based exercise program utilizing footwear that causes exercise with normal daily activity that may significantly improve function in patients with knee pain in general, and specifically knee osteoarthritis (OA).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Physical Therapy
Description: Up to 20 sessions of traditional physical therapy
Study: NCT03749460

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study: NCT00277589

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levothyroxin-Na
Description: 1 tablet 30 minutes before breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine-Na + iodide
Description: 1 tablet 30 minutes before breakfast

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iodide
Description: 1 tablet 30 minutes before breakfast

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet 30 minutes before breakfast
Study: NCT00389090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide and O6-Benzylguanine
Description: O6BG + Temozolomide
Study: NCT01248520

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: influenza and general health information
Description: Subjects assigned to the influenza information group will receive health text messages from the time they enroll until they deliver. These messages will contain general health information as well as information regarding influenza and the importance of vaccination during pregnancy.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: general health information
Description: Subjects assigned to the influenza information group will receive health text messages from the time they enroll until they deliver.
Study: NCT03656458

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Warm Up
Description: 10 low jumps 5 Illiopoase Stretches 5 L/L Abductor Stretches 10 Trunk rotations 10 Should Circumduction Clock wise/Counter clockwise 10 Cervical Rotations Clockwise/Counter Clockwise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warm Up
Description: 10 low jumps 5 Illiopoase Stretches 5 L/L Abductor Stretches 10 Trunk rotations 10 Should Circumduction Clock wise/Counter clockwise 10 Cervical Rotations Clockwise/Counter Clockwise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Balance Training
Description: Internal Protuberances:~1. Looking up/Looking down/looking over the shoulder (Rt. /Lt.) 10 Reps Each~2. Looking behind over the shoulder (Rt. /Lt.)10 Reps~3. Looking Up with overhead Upper Limb Flexion. 5 Reps~4. Reaching out of Base of support (Rt. /Lt. / midline Cross) 10 Reps Each~5. Side to Side weight Shifting 10 Reps~6. Standing on toes/Heels 10 Reps each~External Protuberance:~1. Tuck forward/ Backward/ Sideways(Rt. /Lt.) 10 reps Each~2. Bosu Ball Training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biodex Balance Training
Description: Biodex Balance Training Using Biodex Balance System SD
Study: NCT01194882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HUMAN INSULIN (BIOSYNTHETIC)
Description: Pharmaceutical form: solution for infusion Route of administration: Intraperitoneal use Dose regimen: 400 IU/ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insuplant
Description: Pharmaceutical form:solution for infusion Route of administration: Intraperitoneal use~Dose regimen:
Study: NCT00128245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimecrolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimecrolimus

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Placebo
Study: NCT02766998

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preserved umbilical vein as shunt/conduit
Description: All subjects will have umbilical vein harvested and stored for use in first cardiac surgery requiring shunt or conduit.
Study: NCT04376229

Intervention type: OTHER
Intervention: Registry
Description: Registry of cancer patients who receive proton radiation therapy
Study: NCT04239456

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RehaCom (software)
Description: RehaCom software has gamified, interactive modules that will help participants practice the application of various memory strategies at custom, increasingly more difficult levels. Instructor will also use the software to teach and demonstrate the use of memory strategies with the domains targeted (i.e., list learning, remembering written/verbal information, and memory for names/faces).
Study: NCT00884650

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral analgesic
Description: per clinical standard of care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous analgesic per pump
Description: per clinical standard of care
Study: NCT03831854

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine 300 MG
Description: 300 mg of oral Lamotrigine. One of the key studies in this area was reported at the Society of Neuroscience meeting in 1997 and later published in the Archives of General Psychiatry. This study reported that, in healthy subjects 300 mg oral lamotrigine significantly decreased ketamine-induced perceptual abnormalities as assessed by the Clinician-Administered Dissociative States Scale (P\<.001).31 Furthermore lamotrigine increased the immediate mood-elevating effects of ketamine (P\<.05).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 300 mg of oral Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Description: 1mg/kg bolus at induction followed by 5 microgram/kg/min infusion till the end of the surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: 1mg/kg bolus at induction followed by 5 microgram/kg/min infusion till the end of the surgery
Study: NCT00370110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itopride 100 mg
Description: 100 mg three times daily

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itopride 200 mg
Description: 200 mg three times daily
Study: NCT01542346

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: subcutaneous adaption
Study: NCT02674269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300 IU of BotuGelTM (60ml)
Description: One intravesical instillation of 300 IU of botox in 60 ml of TC-3 gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 IU of BotuGelTM (60ml)
Description: One intravesical instillation of 400 IU of botox in 60 ml of TC-3 gel

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TC-3 Gel
Description: Intravesical instillation of 60 ml TC-3 gel
Study: NCT01705405

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Software for acquiring ultrasound and endoscopic images
Description: Use of a medical device to acquire ultrasound and endoscopic images
Study: NCT01519778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR701 FA
Description: 1 tablet 200 mg once daily
Study: NCT02775838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green
Description: perioperative application of Indocyanine green (ICG)
Study: NCT01913899

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occupational/ physical therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Occupational/ physical therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror therapy
Description: - Intervention group: treatment sessions of 60 minutes with mirror therapy over a period of 14 days starting directly post surgical (24-48 hours)
Study: NCT02272361

Intervention type: OTHER
Group type: OTHER
Intervention: laparoscopic sacrocolpopexy

Intervention type: OTHER
Group type: OTHER
Intervention: vaginal mesh surgery
Study: NCT01265043

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral hygiene intervention
Description: Oral health promotion intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral hygiene intervention
Description: Oral health promotion intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral hygiene intervention
Description: Oral health promotion intervention
Study: NCT02573649

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Closed-loop Stimulation on first
Description: Closed-loop Stimulation algorithm is turned on in the device. The patient performs a head up tilt test. After a week Closed-loop Stimulation algorithm is turned off and the patient performs a second head up tilt test.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Closed-loop Stimulation off first
Description: Closed-loop Stimulation algorithm is turned off in the device. The patient performs a head up tilt test. After a week Closed-loop Stimulation algorithm is turned on and the patient performs a second head up tilt test.
Study: NCT03845712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxecitine and doxribtimine
Description: Doxecitine and doxribtimine is administered orally in 3 equal doses given approximately 6 to 8 hours apart. Doxecitine and doxribtimine is administered with food.
Study: NCT02378636

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 600S
Description: Monofocal Aspheric Intraocular Lens (IOL)
Study: NCT04695652

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVC-COV1901(S protein with adjuvant)
Description: Approximately 3180 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) and Visit 4 (Day 29) via intramuscular (IM) injection in the deltoid region

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: MVC-COV1901(Saline)
Description: Approximately 530 participants will receive 2 doses of MVC-COV1901(Saline) at Visit 2 (Day 1) and Visit 4 (Day 29) via IM injection in the deltoid region
Study: NCT02164019

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: long-stem cemented hemiarthroplasty (LSCH)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intramedullary nailing (IMN)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: questionnaires

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: questionnaires
Study: NCT00232219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fish oil
Study: NCT04434118

Intervention type: DRUG
Intervention: Traditional antirheumatic drugs
Description: Hydroxychloroqine, Methotrexate, Glucocorticoids, Leflunomide, and Sulphasalazine

Intervention type: DRUG
Intervention: Traditional antirheumatic drugs
Description: Hydroxychloroqine, Methotrexate, Glucocorticoids, Leflunomide, and Sulphasalazine
Study: NCT01375751

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: d by subcutaneous injection
Study: NCT04739410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: Ivermectin Prescribing protocol: Participants were prescribed Ivermectin 12 mg per oral stat and then 12 mg per oral after 12 hours and 12 mg per oral after 24 hours and we looked at the response at day 7 on follow up in terms of improvement of symptoms like (Fever, Cough, sore throat, Headache, Shortness of breath, lethargy, and fatigue.Any side effects of the drugs were noted as well

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ivermectin
Description: Ivermectin Prescribing protocol: Participants were prescribed Ivermectin 12 mg per oral stat and then 12 mg per oral after 12 hours and 12 mg per oral after 24 hours and we looked at the response at day 7 on follow up in terms of improvement of symptoms like (Fever, Cough, sore throat, Headache, Shortness of breath, lethargy, and fatigue.Any side effects of the drugs were noted as well